Longevity Peptides: BPC-157, MOTS-C, TB-500 and What We Still Do Not Know

The longevity peptides BPC-157, MOTS-C and TB-500 have not been shown to extend life, improve healthspan or prevent an age-related disease in humans. There is no validated longevity dose for any of them. Interesting preclinical biology and a handful of BPC-157 exposures are not evidence of an effective treatment.

Recent regulatory news has made the distinction harder to see. In July 2026, an FDA advisory committee narrowly recommended that several of these substances be considered for the US 503A pharmacy-compounding bulks list. That vote was advisory: it did not approve BPC-157, MOTS-C or TB-500 as drugs, validate a dose or demonstrate benefit. FDA's scientific reviewers had recommended against listing them, and a final agency determination remained pending at this review date.

Clinical and editorial review: August 4, 2026. We reviewed the English-language search results that day for “peptides for longevity”, “BPC-157 benefits and risks”, “MOTS-C peptide” and “TB-500 peptide”, alongside Spanish queries for “péptidos para longevidad” and the three compounds. Search intent combines education, purchasing and injection protocols. The most important gap is a product-specific account of human evidence, regulation and quality that does not turn vendor dosing into medical advice. This guide is educational and does not replace individual care.

At a glance: what do we know about each peptide?

Substance	Common claim	Best available human evidence	Clinical position today
BPC-157	Tendon, gut and joint repair; faster recovery.	Small, short studies: one ulcerative-colitis trial abstract, uncontrolled bladder and knee reports, and IV safety in two people. No longevity trial.	Do not recommend outside regulated research. Effective dosing and long-term safety are unknown.
MOTS-C	AMPK activation, metabolism, insulin sensitivity, endurance and mitochondrial aging.	Associations involving the MOTS-C made by the body, plus cell and animal research. FDA found no published human administration of exogenous MOTS-C.	Investigational. A mitochondrial mechanism is not a clinical outcome.
TB-500	Wound, muscle, tendon and ligament recovery.	FDA found no human clinical study or exposure data for the TB-500 fragment. Full-length thymosin beta-4 studies are not interchangeable.	Investigational. Identity, efficacy, pharmacokinetics and human risks remain uncharacterised.
Peptide stacks	Combining BPC-157 + TB-500 or other products to add effects.	No human trial establishes efficacy, interactions or safety of these combinations for longevity or recovery.	More uncertainty, not more evidence. A stack also obscures the cause of benefit or harm.

“Peptide” is a chemical description, not a safety certificate

A peptide is a chain of amino acids. Insulin, semaglutide and tesamorelin show that peptides can become valuable medicines. Each approved product, however, had to establish product identity, purity, stability, dose, pharmacokinetics, benefit and harm for a defined population and indication.

Sharing the word “peptide” does not transfer that evidence to BPC-157, MOTS-C or TB-500. It would be like assuming every small molecule works because aspirin works. Our evidence map of longevity treatments applies the same distinction: mechanism, biomarker and patient outcome sit on different rungs.

Approved, off-label, compounded and RUO are not synonyms

Category	What it means	What it does not mean
Approved medicine	A regulator reviewed a specific product, manufacturing process, indication, dose and benefit-risk balance.	It does not prove a longevity benefit or another unstudied use.
Off-label use	An already approved drug is prescribed outside part of its label with a clinical rationale.	A never-approved substance cannot become off-label by being prescribed.
US compounded product	A pharmacy prepares an individual formulation under a specific legal framework. The finished product is not FDA-approved.	Compounded does not mean approved, and US compounding rules do not create authorisation in Europe.
Research use only (RUO)	Material intended for laboratory research, not treatment.	It does not guarantee identity, potency, purity, sterility or safety for injection.

In the EU, a product marketed to modify physiology or treat disease has to meet medicines law. Spain's AEMPS warns that unevaluated products or medicines bought outside legal channels lack the expected safeguards for quality, safety and efficacy. A vial shipped by a website or marked “research only” does not gain Spanish or EU authorisation.

What the FDA committee did—and did not—decide in July 2026

The Pharmacy Compounding Advisory Committee meeting considered BPC-157 for ulcerative colitis, TB-500 for wound healing and MOTS-C for obesity and osteoporosis. It was not an assessment of lifespan or healthspan. FDA reviewers proposed that neither the free-base nor acetate forms be added, citing poor characterisation and insufficient efficacy and safety data.

The external committee then voted narrowly to recommend the substances. That non-binding advice informs a regulatory process; it does not replace it. On August 4, FDA's current compounding safety-risk page still highlighted immunogenicity, aggregation, peptide-related impurities and insufficient human safety information. “FDA approved these peptides” is therefore a false summary.

BPC-157: a large animal literature and a tiny human one

BPC-157 is a synthetic 15-amino-acid peptide studied in rodent models of gastrointestinal, tendon, vascular and neurological injury. Signals involving healing, angiogenesis and nitric-oxide pathways are biologically interesting. They are not patient outcomes. A treated rat tendon does not tell us whether a person will regain function, avoid recurrence or remain safe after months of exposure.

The best human comparison does not establish efficacy

The FDA BPC-157 review identified one multicentre trial abstract. Fifty-three people with reportedly mild-to-moderate ulcerative colitis were assigned to an 80 mg daily enema or placebo for two weeks; 46 completed. Disease-activity scores changed by -3.2 points with BPC-157 and -1.6 with placebo. The estimated 1.6-point between-group difference had a 95% confidence interval from -4.84 to 1.62, compatible with benefit or no benefit. Eligibility, endpoint details, analysis and follow-up were incomplete.

The remaining human reports are even less decisive:

• Interstitial cystitis: 12 women aged 39-76 received one 10 mg intravesical procedure. All reported improvement at six weeks and no adverse events, but there was no placebo, blinding or comparison group. A 12/12 open-label result can reflect selection, expectation and regression to the mean.
• Knee pain: 17 people received one or two 2-4 mg intra-articular injections in a retrospective series with incomplete follow-up. Reported pain relief is not proof of tendon or cartilage repair.
• Intravenous safety: two healthy adults received 10 mg on day one and 20 mg on day two. No immediate problem was observed, but n=2 cannot detect uncommon events or chronic harm.

FDA also found three FAERS reports linked to injected BPC-157, including a local reaction, shortness of breath requiring an emergency visit and pigmentation changes after a BPC-157/TB-500 product. Spontaneous reports cannot establish causality or incidence. The useful conclusion is not that harm occurs at a known percentage; it is that the real frequency and range of harm are unknown.

MOTS-C: measuring an endogenous peptide does not validate an injection

MOTS-C is a peptide encoded by a small mitochondrial-DNA open reading frame. Cell and mouse studies suggest links to AMPK signalling, metabolic homeostasis, insulin sensitivity and stress adaptation. Researchers have also measured the body's own MOTS-C in people during exercise and metabolic experiments.

Those observations do not show that injected synthetic MOTS-C produces the same response. The FDA MOTS-C review found no published human administration by any route, no human pharmacokinetics and insufficient toxicology to quantify efficacy or safety in obesity, osteoporosis or longevity. In human blood tested in vitro, MOTS-C was rapidly degraded; whether an injection creates an active concentration, and for how long, remains unknown.

There is therefore no human effect size and no evidence-based dose. The 5 mg and 10 mg vial strengths proposed in a compounding submission are product requests, not validated regimens. Our guide to mitochondrial dysfunction and aging explains why an AMPK pathway or mitochondrial marker cannot stand in for a clinical benefit.

TB-500: do not substitute full-length thymosin beta-4 evidence

TB-500 usually refers to the seven-amino-acid LKKTETQ fragment associated with thymosin beta-4. The full protein has been investigated in other settings, but a fragment can have different stability, distribution and activity. Trials of full-length thymosin beta-4 cannot be treated as indirect proof that a TB-500 vial heals an injury.

The FDA TB-500 review found no clinical study, human pharmacokinetic data or published exposure to TB-500 by any route. It also found no authorised product in the US, EU, Spain or several other countries. Without a standardised pharmaceutical identity, the concentration printed on a grey-market vial does not tell us reliably what it contains or how it will behave.

Why this guide does not publish a dosing protocol

A clinical dose is not established by copying the most common number from forums. Dose-ranging studies must connect amount, route, exposure, response, toxicity and interactions. BPC-157's exploratory human doses span an enema, bladder injection, joint injection and IV infusion; those routes are not interchangeable. For MOTS-C and TB-500, FDA found no published human administration data. A micrograms-per-kilogram table would offer false precision.

There is no validated BPC-157 + TB-500 stack either. Combining poorly characterised substances adds uncertainty around interactions, immunogenicity and attribution. If harm occurs, it may be impossible to separate the active ingredient from an impurity, contamination, excipient or combination effect.

Risks start with the vial and extend to the immune system

• Identity and potency: inconsistent names, free-base versus acetate forms and unverified concentrations.
• Impurities and aggregates: synthesis and degradation can create peptide variants; aggregation may change exposure and immunogenicity.
• Sterility and endotoxins: critical for every injectable. A vendor certificate is not independent testing of the finished product.
• Immune response: possible outcomes range from antibodies without symptoms to severe allergy; incidence is not quantified.
• Systemic effects and interactions: inadequately characterised. “Natural” or “made by the body” does not make another dose and route predictable.
• Opportunity cost: delaying rehabilitation, injury diagnosis, approved obesity or osteoporosis treatment, or prevention that changes outcomes.

In June 2026, Australia's TGA and Chief Medical Officer warned of hospitalisations and serious events associated with unapproved peptide products, including liver injury and severe allergic reactions. The data do not assign each case to BPC-157 or TB-500, but they do refute the idea that the grey market is harmless.

Red flags after an injection

Breathing difficulty, lip or tongue swelling, fainting, chest pain, confusion, one-sided weakness, high fever, severe pain or spreading redness around an injection need urgent assessment. A hot lump, discharge, widespread rash, dark urine or yellowing of the eyes or skin also warrants medical review. Bring the vial, label, batch, approximate dose and timing; do not re-dose to “confirm” a reaction.

Athletes face an additional risk

The 2026 WADA Prohibited List includes BPC-157 as an unapproved substance, TB-500 among thymosin beta-4 derivatives and MOTS-C as a metabolic modulator. They are prohibited at all times. Contamination, mislabelling or a clinic recommendation does not remove anti-doping responsibility.

Decision table: start with the goal, not the peptide

If your goal is...	Define first	Better-supported options today	When to investigate further
Recover a tendon or joint	Diagnosis, tolerated load, strength, range, trauma and red flags.	Progressive rehabilitation, load management, indicated analgesia and referral for rupture or locking.	Severe night pain, fever, a hot joint, inability to bear weight, neurological deficit or failed treatment.
Improve metabolism or weight	BMI, waist, pressure, glucose, lipids, sleep, medicines and baseline risk.	Nutrition, activity, sleep and approved obesity/diabetes treatment when indicated.	Unexplained weight change, endocrine symptoms, complications or insufficient response.
Preserve muscle with age	Strength, function, intake, muscle mass, disease and medication.	Progressive resistance training, adequate protein and treatment of causes; see our sarcopenia guide.	Falls, rapid weakness, weight loss, swallowing problems or functional decline.
“Optimise longevity”	The patient outcome you want to change and your absolute risk.	Blood pressure, ApoB/LDL, glucose, exercise, sleep, vaccines and indicated screening—not one biomarker.	When a regulated trial offers a protocol, control group, follow-up and relevant clinical outcomes.

Eight questions a clinic should be able to answer

1. What is the diagnosis and which clinical outcome should improve?
2. Is this exact product authorised where I will receive it?
3. Which controlled human trial supports this indication, route and dose?
4. What absolute benefit should I expect, and over what period?
5. Who made the finished product and how were identity, sterility, endotoxins, aggregation and potency tested?
6. What are the risks, interactions, stopping rules and adverse-event reporting process?
7. Which approved or non-drug alternatives were considered?
8. What happens if I choose not to use it?

Vague answers such as “it activates your mitochondria”, “everyone uses this dose” or “it is natural and has no side effects” are warning signs. Our guide to choosing a longevity clinic expands the checklist, while our biohacking evidence guide shows how to ask for an objective, dose, metric and safety plan without confusing novelty with evidence.

What changes in clinic today—and what does not

What changes: clinicians should ask directly about peptides, RUO vials and stacks because patients may not regard them as medicines. Previous use should be documented without blame: product, batch, route, dose, dates, symptoms and relevant testing. Suspected reactions should be reported through the appropriate pharmacovigilance route.

What does not: there is no basis to add BPC-157, MOTS-C or TB-500 to a longevity protocol. A regulatory vote, animal mechanism, testimonial or uncontrolled improvement in pain cannot replace a trial with a defined population, dose, outcome and follow-up. Our longevity biomarkers guide explains why measurement should lead to a useful decision.

Sources and certainty

• FDA, July 23-24, 2026 PCAC meeting: official agenda, reviewed uses and briefing materials.
• FDA BPC-157 briefing: characterisation, human studies, exploratory doses, adverse reports and scientific recommendation.
• FDA MOTS-C briefing: no published human administration and major product/safety gaps.
• FDA TB-500 briefing: no clinical exposure, distinction from thymosin beta-4 and international status.
• BPC-157 interstitial-cystitis pilot: 12 women, 10 mg once, no comparator.
• BPC-157 IV safety pilot: two adults and acute follow-up; not an efficacy trial.
• 2026 review of approved and unapproved peptides in sport/injury care: evidence and regulatory framework.
• AEMPS, illegal medicines: authorisation and safe supply channels in Spain.
• 2026 WADA Prohibited List: anti-doping status.

Certainty is very low for a clinical BPC-157 benefit and absent for human benefit from administered MOTS-C or TB-500 products. No adverse event in a tiny study is not proof of safety. We will update this guide if controlled human trials, final regulatory decisions or pharmacovigilance alerts change the conclusion.

If you are considering a peptide because of pain, fatigue, muscle loss or metabolic risk, the useful first step is to define the problem and the options that change outcomes. Progevita can help structure that assessment through preventive medicine and measurable follow-up. Talk to the team without obligation, and bring the label of anything you already use.